Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Clinical trial NCT07646145 · RECRUITING
Trial details
- NCT number
- NCT07646145
- Sponsor
- Shanxi Province Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-01
- Primary completion
- 2027-04-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.